

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1649JXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Feb 2 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 Expanded CAPlus Coverage of US, Japanese, WIPO,
EPO, and German patents
NEWS 3 Feb 1 Addition of Machine-Translated Abstracts to CAPlus
NEWS 4 Feb 28 Patent Information Now Searchable in CAOLD
NEWS 5 Mar 20 INPADOC: PRODUCER WARNING ABOUT DATA DELAYS
NEWS 6 Mar 22 NEW FEATURES IN INPADOC - RANGE SEARCHING AND NEW
SDI/UPDATE SEARCH FIELD
NEWS 7 May 1 Beilstein Abstracts on STN - FILE BABS
NEWS 8 May 1 RN CROSSOVER AND ANSWER SIZE LIMITS INCREASED
NEWS 9 May 1 AIDSLINE has been reloaded
NEWS 10 May 1 Searching Y2-K compliant Patent Numbers
NEWS 11 May 9 Sequence Similarity Batch Search in DGENE
NEWS 12 May 19 Weekly Statistics for New Entries now available
in INPADOC
NEWS 13 May 22 CITED REFERENCES NOW AVAILABLE IN CAPLUS AND CA FILE
NEWS 14 May 22 POSTPROCESSING OF SEARCH RESULTS MAY BE AFFECTED
BY ADDITION OF CITED REFERENCES TO CAPLUS, CA,
REGISTRY, CASREACT, MARPAT, and MARPATPREV
NEWS 15 Jun 2 KOREAN PATENTS NOW IN CAS DATABASES
NEWS 16 Jun 20 WIPO/PCT Patents Fulltext Database now on STN

NEWS EXPRESS FREE UPGRADE 5.0C NOW AVAILABLE
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:28:51 ON 22 JUN 2000

=> file medline biosis embase caplus

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'MEDLINE' ENTERED AT 15:29:52 ON 22 JUN 2000

FILE 'BIOSIS' ENTERED AT 15:29:52 ON 22 JUN 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 15:29:52 ON 22 JUN 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:29:52 ON 22 JUN 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s trre (s) polypeptide

L1 0 TRRE (S) POLYPEPTIDE

=> s trre (s) protein

L2 0 TRRE (S) PROTEIN

=> s trre

L3 9 TRRE

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 6 DUP REM L3 (3 DUPLICATES REMOVED)

=> d l4 ibib kwic

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:736749 CAPLUS
DOCUMENT NUMBER: 132:2794
TITLE: Modulators affecting tumor necrosis factor
receptor-releasing enzyme activity
INVENTOR(S): Gatanaga, Tetsuya; Granger, Gale A.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958559	A2	19991118	WO 1999-US10793	19990514
WO 9958559	A3	20000120		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,			

CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1998-81385 19980514
AB The biol. effects of the cytokine tumor necrosis factor (TNF) are mediated

by binding to receptors on the surface of cells. Nine new proteins and polynucleotides are provided that promote enzymic cleavage and release of TNF receptors. The isolated polynucleotides have the following properties: (a) the sequence is expressed at the mRNA level in Jurkat T cells; (b) when COS-1 cells expressing TNF-receptor are genetically transformed to express the sequence, the cells have increased enzymic activity for cleaving and releasing the receptor. Also provided are screening methods for identifying addnl. compds. that influence TNF receptor shedding. **TRRE** activity alleviates septic shock and decreases tumor necrotizing activity, and the modulator expression products are effective in treating septic shock. As the active ingredient in a pharmaceutical compn., the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathol. of disease.

=> file medline biosis embase caplus uspatfull

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.87	12.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.56	-0.56

FILE 'MEDLINE' ENTERED AT 15:32:44 ON 22 JUN 2000

FILE 'BIOSIS' ENTERED AT 15:32:44 ON 22 JUN 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 15:32:44 ON 22 JUN 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 15:32:44 ON 22 JUN 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:32:44 ON 22 JUN 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

=> s trre

L5 11 TRRE

=> dup rem l5

PROCESSING COMPLETED FOR L5
L6 8 DUP REM L5 (3 DUPLICATES REMOVED)

=> d l6 ibib kwic total

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:736749 CAPLUS

DOCUMENT NUMBER: 132:2794
 TITLE: Modulators affecting tumor necrosis factor
 receptor-releasing enzyme activity
 INVENTOR(S): Gatanaga, Tetsuya; Granger, Gale A.
 PATENT ASSIGNEE(S): The Regents of the University of California, USA
 SOURCE: PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958559	A2	19991118	WO 1999-US10793	19990514
WO 9958559	A3	20000120		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
 MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
 TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-81385 19980514
 AB The biol. effects of the cytokine tumor necrosis factor (TNF) are mediated by binding to receptors on the surface of cells. Nine new proteins and polynucleotides are provided that promote enzymic cleavage and release of TNF receptors. The isolated polynucleotides have the following properties: (a) the sequence is expressed at the mRNA level in Jurkat T cells; (b) when COS-1 cells expressing TNF-receptor are genetically transformed to express the sequence, the cells have increased enzymic activity for cleaving and releasing the receptor. Also provided are screening methods for identifying addnl. compds. that influence TNF receptor shedding. ~~TRRE~~ activity alleviates septic shock and decreases tumor necrotizing activity, and the modulator expression products are effective in treating septic shock. As the active ingredient in a pharmaceutical compn., the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathol. of disease.

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1998:324897 CAPLUS
 DOCUMENT NUMBER: 129:13976
 TITLE: Isolated tumor necrosis factor receptor releasing enzyme and pharmaceutical compositions comprising the enzyme
 INVENTOR(S): Granger, Gale A.; Gatanaga, Tetsuya
 PATENT ASSIGNEE(S): Regents of the University of California, USA;
 Granger,
 Gale A.; Gatanaga, Tetsuya
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9820140	A1	19980514	WO 1997-US19930	19971105
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9851621	A1	19980529	AU 1998-51621	19971105
EP 938548	A1	19990901	EP 1997-946457	19971105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NO 9902187	A	19990701	NO 1999-2187	19990505
PRIORITY APPLN. INFO.: US 1996-30761 19961106				
WO 1997-US19930 19971105				
AB A human tumor necrosis factor receptor releasing enzyme (TRRE) is prepd. from a cultured human cell line THP-1 (human monocytic leukemia) stimulated with PMA and characterized. The native form of TRRE exhibits a mol. wt. of 120 kDa on SDS-PAGE. Its enzyme activity is sensitive to metalloprotease inhibitor, but not to serine or cysteine protease inhibitor. A compn. contg. TRRE for treating a disease assocd. with altered levels of tumor necrosis factor is also described. Also claimed are methods of (1) diagnosing and treating cancer or inflammation assocd. with TREE and (2) administration of pharmaceutical compns. contg. TREE . Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the case of diseases assocd. with elevated levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amt. sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of TRRE is decreased at the disease site.				
L6 ANSWER 3 OF 8 BIOSIS COPYRIGHT 2000 BIOSIS				
ACCESSION NUMBER: 1996:257458 BIOSIS				
DOCUMENT NUMBER: PREV199698813587				
TITLE: Identification and characterization of soluble TNF receptor releasing enzyme (TRRE) from PMA-stimulated human monocytic THP-1 cells.				
AUTHOR(S): Katsura, K. (1); Park, M. (1); Gatanaga, M. (1); Takishima, K.; Granger, G. A. (1); Gatanaga, T. (1)				
CORPORATE SOURCE: (1) Univ. Calif., Irvine, CA USA				
SOURCE: Proceedings of the American Association for Cancer Research				
Annual Meeting, (1996) Vol. 37, No. 0, pp. 492.				
Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research Washington, D.C., USA				
April 20-24, 1996				
ISSN: 0197-016X.				
DOCUMENT TYPE: Conference				
LANGUAGE: English				
TI Identification and characterization of soluble TNF receptor releasing enzyme (TRRE) from PMA-stimulated human monocytic THP-1 cells.				

L6 ANSWER 4 OF 8 MEDLINE
 ACCESSION NUMBER: 96222497 MEDLINE
 DOCUMENT NUMBER: 96222497
 TITLE: Identification of the proteolytic enzyme which cleaves human p75 TNF receptor in vitro.
 AUTHOR: Katsura K; Park M; Gatanaga M; Yu E C; Takishima K; Granger
 CORPORATE SOURCE: G A; Gatanaga T
 SOURCE: Department of Molecular Biology and Biochemistry, University of California, Irvine 92717-3900, USA.
 PUB. COUNTRY: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1996 May 15) 222 (2) 298-302.
 LANGUAGE: Journal code: 9Y8. ISSN: 0006-291X.
 ENTRY MONTH: United States
 FILE SEGMENT: Journal; Article; (JOURNAL ARTICLE)
 ENTRY MONTH: English
 ENTRY MONTH: Priority Journals; Cancer Journals
 ENTRY MONTH: 199610

AB . . . fragments, respectively. In this study, the enzymatic activity involved in the cleavage of human p75 TNF-R, named TNF-R releasing enzyme (TRRE), was identified in the culture supernatant of PMA-stimulated THP-1 cells using an activity assay system established by our group. When THP-1 cells were stimulated with PMA, TRRE was released rapidly into the supernatant, reaching maximal activity within 3 hours. The release of TRRE into the culture supernatant depended on the concentration of PMA and FCS. TRRE activity was partially inhibited by chelating agents, suggesting that TRRE may be a metallo-protease-like enzyme. This is the first successful attempt to establish a stable TRRE source with a reliable assay system.

L6 ANSWER 5 OF 8 USPATFULL
 ACCESSION NUMBER: 93:83356 USPATFULL
 TITLE: Facsimile apparatus comprising means for continuously transmitting plural groups of image data to the same receiver party
 INVENTOR(S): Hamano, Hiroaki, Osaka, Japan
 Nakajima, Akio, Toyokawa, Japan
 PATENT ASSIGNEE(S): Minolta Camera Kabushiki Kaisha, Osaka, Japan
 (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5251043	19931005
APPLICATION INFO.:	US 1991-776636	19911015 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1990-277402	19901015
	JP 1990-277403	19901015
	JP 1990-277404	19901015
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Coles, Sr., Edward L.	
ASSISTANT EXAMINER:	Rogers, Scott A.	
LEGAL REPRESENTATIVE:	William Brinks Olds Hofer Gilson & Lione	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 31 Drawing Page(s)	
LINE COUNT:	1632	

DETD . . . key 52 is referred to as a TR key, and the transmission reservation key 57 is referred to as a TRRE key.

L6 ANSWER 6 OF 8 BIOSIS COPYRIGHT 2000 BIOSIS
 ACCESSION NUMBER: 1993:227104 BIOSIS
 DOCUMENT NUMBER: PREV199395118279
 TITLE: Do birch trees (Betula pendula) grow better if foraged by wood ants.
 AUTHOR(S): Mahdi, T.; Whittaker, J. B.
 CORPORATE SOURCE: Biological Sci. Div., Inst. Environmental and Biological Sci., Univ. Lancaster, Lancaster LA1 4YQ UK
 SOURCE: Journal of Animal Ecology, (1993) Vol. 62, No. 1, pp. 101-116.
 ISSN: 0021-8790.
 DOCUMENT TYPE: Article
 LANGUAGE: English
 AB. . . of the insect herbivore community on Betula pendula is markedly changed by F. rufa predation, the effect of this on **trre** growth is slight.

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 1985:1908 CAPLUS
 DOCUMENT NUMBER: 102:1908
 TITLE: The tolerance of tree lucerne to some soil-applied herbicide
 AUTHOR(S): Hurrell, G. A.; Bourdot, G. W.
 CORPORATE SOURCE: Agric. Res. Div., MAF, Lincoln, N. Z.
 SOURCE: Proc. N. Z. Weed Pest Control Conf. (1984), 37th, 210-12
 CODEN: PZWPAL; ISSN: 0370-2804
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT Plant growth and development
 (by **trre** lucerne, soil-applied herbicides effect on)

L6 ANSWER 8 OF 8 USPATFULL
 ACCESSION NUMBER: 78:39684 USPATFULL
 TITLE: Method for data transmission and a system for carrying out the method
 INVENTOR(S): Westman, Kjell Harry, Vallingby, Sweden
 PATENT ASSIGNEE(S): U.S. Philips Corporation, New York, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4103288	19780725
APPLICATION INFO.:	US 1976-723155	19760914 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1975-10432	19750918
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Pitts, Harold I.	
LEGAL REPRESENTATIVE:	Trifari, Frank R.; Biren, Steven R.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1087	

DETD . . . and input of which are connected to a central station 1 via a belonging modem M1 and a transmission/reception circuit **TRRE**, respectively. To the loop are connected four terminal stations 2, 3, 4, 5 via the belonging modems M2, M3, M4. . .
 DETD In FIG. 5 is disclosed an embodiment of the transmission/reception

circuit **TRRE**, through which the central station 1 (TC) (FIG. 1) is connected to the series transmission loop. The horizontal line at.

. . figure represents the border line with respect to the central station 1 with the signals shown which are interchanged between **TRRE** and TC. The horizontal line at the bottom of the figure represents the border line with respect to the transmission. . .
DETD **TRRE** is composed of a central control unit CO, in which is comprised control circuits of a type well known by. . .
DETD On the input side **TRRE** comprises a central control unit CO to be described in more detail with reference to FIG. 7 and is furthermore.

DETD . . . diagram of the DT, DTI respectively, circuit comprised in the connection circuit (FIG. 4) of each terminal and in the **TRRE** circuit of the central station (FIG. 5).

DETD The central control unit CO (FIG. 5) of **TRRE** is disclosed in FIG. 7. CO is composed of a 4 bit counter COUNT4 which may be controlled so as. . .

DETD . . . and DT in all terminal stations, which are thereby brought into synchronism. The SYN characters are received in IDBR of **TRRE** after having circulated the loop and are decoded in DTI, which will then activate its SYN output, which will in. . .

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	14.99	27.28
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.11	-1.67

STN INTERNATIONAL LOGOFF AT 15:33:26 ON 22 JUN 2000

07200 354

09700354 Results

SEQ ID NO: 9

RESULT 10

G22793/c

LOCUS G22793 405 bp DNA STS 31-MAY-1996

DEFINITION human STS WI-11758, sequence tagged site.

ACCESSION G22793

VERSION G22793.1 GI:1343119

KEYWORDS STS; STS sequence; primer; sequence tagged site.

SOURCE human STSs derived from sequences in dbEST and the Unigene collection.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 405)

AUTHORS Hudson, T.

TITLE Whitehead Institute/MIT Center for Genome Research; Physically Mapped STSs

JOURNAL Unpublished (1995)

COMMENT

Contact: Thomas Hudson
 Whitehead Institute/MIT Center for Genome Research
 Whitehead Institute for Biomedical Research
 9 Cambridge Center, Cambridge MA 02142 USA
 Tel: 617 252 1900
 Fax: 617 252 1902
 Email: thudson@genome.wi.mit.edu

Primer A: TTTTTCCTCTTTTATTAAGTCCGC

Primer B: TGATGGTGATCTTGGCACTC

STS size: 127

PCR Profile:

Presoak:

Denaturation:

Annealing: 56 degrees C

Polymerization:

PCR Cycles: 35

Thermal Cycler:

Protocol:

Template: 10 ng

Primer: each 5 pM

dNTPs: each 4 nM

Taq Polymerase: 0.025 units/ul

Total Vol: 20 ul

Buffer:

MgCl2: 1.5 mM

KCl: 50 mM

Tris-HCL: 10 mM

pH: 9.3

Derived from dbEST (genbank accession R12670).

FEATURES

source

Location/Qualifiers

1..405

/organism="Homo sapiens"

/db_xref="taxon:9606"

/map="355.3 cR from top of Chr17 linkage group"

STS

14..140

primer_bind

14..37

primer_bind

complement(121..140)

BASE COUNT

92 a 107 c 100 g 100 t 6 others

ORIGIN

Query Match 27.9%; Score 330.6; DB 54; Length 405;

Best Local Similarity 96.7%; Pred. No. 1.8e-69;

Matches 356; Conservative 0; Mismatches 9; Indels 3; Gaps 2;

Qy	756	CTGGAGCCTAAGCTGGACC -- TGCTACTGGAGAAGACCAAGGAGCTGCAGAAGCTGATTG	813
Db	400	CTGGAGCCTAAGCTGGACCCTGCCTACTGGANAAGCCCAAGGAGCTGCAGAAGCTGANTG	341
Qy	814	AAGCTGA-CATCTCCAAGAGGTACACGGGCGCCCTGTGAACCTGATGGGAACCTCTCTG	872
Db	340	AAGCTGACCATCTCCAANAGGTACACGGGCGCCCTGTGAACCTGATGGGAACCTCTCTG	281
Qy	873	TGACACCCTCCGTGTTCTTGCCCTGCCCATCTTCTCCGCTTTTGGGATGAAGATGATAGCC	932
Db	280	TGANACCCTCCGTGNTCTTGCCCTGCCCATCTTCTCCGCTTTTGGGATGAAGATGATAGCC	221
Qy	933	AGGGCTGTTGTTTTGGGGCCCTTCAAGGCAAAGACCAGGCTGACTGGAAGATGGAAAGC	992
Db	220	AGGGCTGTTGTTTTGGGGCCCTTCAAGGCAAAGACCAGGCTGACTGGAAGATGGAAAGC	161
Qy	993	CACAGGAAGGAAGCGGCACCTGATGGTGATCTTGGCACTCTCCATGTTCTCTACAAGAAG	1052
Db	160	CACAGGAAGGAAGCGGCACCTGATGGTGATCTTGGCACTCTCCATGTTCTCTACAAGAAG	101
Qy	1053	CTGTGGTGATTGGCCCTGTGGTCTATCAGGCGAAAACACAGATTCTCCTTCTAGTTAGT	1112
Db	100	CTGTGGTGATTGGCCCTGTGGTCTATCAGGCGAAAACACAGATTCTCCTTCTAGTTAGT	41
Qy	1113	ATAGCGCA	1120
Db	40	ATAGCGGA	33

CC expressing the receptor. The present sequence represents a specifically
CC claimed clone which affects tumour necrosis factor receptor releasing
CC enzyme (TRRE) activity. Methods from the present invention can be used to
CC assess a disease condition associated with altered TRRE activity. The
CC polypeptides, polynucleotides and antibodies can be used to decrease or
CC increase signal transduction from a cytokine in a cell. The polypeptides,
CC polynucleotides and antibodies may be used to treat heart failure,
CC cachexia, inflammation, endotoxic shock, arthritis, multiple sclerosis
CC and sepsis, and cancer.

XX

SQ Sequence 1187 BP; 278 A; 288 C; 369 G; 252 T; 0 other;

Query Match 100.0%; Score 1187; DB 21; Length 1187;
Best Local Similarity 100.0%; Pred. No. 5.4e-281;
Matches 1187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 GAGCTCGCGCGCTGCAGGTCGACACTAGTGGATCCAAAGAATTCGGCACGAGGGAAACT 60
      |||
Db      1 gagctcgcgcgcctgcaggtcgacactagtggatccaagaattcggcacgagggaaact 60

Qy     61 CAACGGTGTACGAGTGGAGGACAGGGACAGAGCCCTCTGTGGTGGAAACGACCCACCTCG 120
      |||
Db     61 caacggtgtacgagtggaggacagggacagagccctctgtggtggaacgacccacctcg 120

Qy    121 AGGAGCTTCCTGAGCAGGTGGCAGAAGATGCGATTGACTGGGGCGACTTTGGGGTAGAGG 180
      |||
Db    121 aggagcttcctgagcaggtggcagaagatgcgattgactggggcgactttggggtagagg 180

Qy    181 CAGTGTCTGAGGGGACTGACTCTGGCATCTCTGCCGAGGCTGCTGGAATCGACTGGGGCA 240
      |||
Db    181 cagtgtctgaggggactgactctggcatctctgccgaggctgctggaatcgactggggca 240

Qy    241 TCTTCCCGGAATCAGATTCAAAGGATCCTGGAGGTGATGGGATAGACTGGGGAGACGATG 300
      |||
Db    241 tcttcccggaatcagattcaaaggatcctggaggtgatgggatagactggggagacgatg 300

Qy    301 CTGTTGCTTTGCAGATCACAGTGTGGAAGCAGGAACCCAGGCTCCAGAAGGTGTTGCCA 360
      |||
Db    301 ctgttgctttgcagatcacagtgtggaagcaggaacccaggctccagaaggtgttgcca 360

Qy    361 GGGGCCCAGATGCCCTGACACTGCTTGAATACACTGAGACCCGGAATCAGTTCCTTGATG 420
      |||
Db    361 ggggccagatgccctgacactgcttgaatacaactgagaccggaatcagttccttgatg 420

Qy    421 AGCTCATGGAGCTTGAGATCTTCTTAGCCAGAGAGCAGTGGAGTTGAGTGAGGAGGCAG 480
      |||
Db    421 agctcatggagcttgagatcttcttagccagagagcagtgagggtgagtgaggagcag 480

Qy    481 ATGTCTGTCTGTGAGCCAGTTCAGCTGGCTCCAGCCATCTGCAGGGCCAGACCAAAG 540
      |||
Db    481 atgtctgtctgtgagccagttccagctggctccagccatctgcagggccagaccaaag 540

Qy    541 AGAAGATGGTTACCATGGTGTGTCAGTGTGAGGATCTGATTGGCAAGCTTACCAGTCTTC 600
      |||
Db    541 agaagatggttaccatgggtgtcagtgtgaggatctgattggcaagcttaccagtcttc 600

Qy    601 AGCTGCAACACCTGTTTATGATCCTGGCCTCACCAAGGTATGTGGACCGAGTGACTGAAT 660
      |||
Db    601 agctgcaacacctgtttatgatcctggcctcaccaaggtatgtggaccgagtgactgaat 660

Qy    661 TCCTCCAGCAAAAGCTGAAGCAGTCCAGCTGCTGGCTTTGAAGAAAGAGCTGATGGTGC 720
      |||
Db    661 tcctccagcaaaagctgaagcagtcagctgctggctttgaagaaagagctgatggtgc 720

Qy    721 AGAAGCAGCAGGAGGCACTTGAGGAGCAGGCGGCTCTGGAGCCTAAGCTGGACCTGCTAC 780
      |||
Db    721 agaagcagcagggaggcacttgaggagcaggcggtctggagcctaagctggacctgctac 780

Qy    781 TGGAGAAGACCAAGGAGCTGCAGAAGCTGATTGAAGCTGACATCTCCAAGAGGTACAGCG 840
      |||
```

Db 781 tggagaagaccaaggagctgcagaagctgattgaagctgacatctccaagaggtacagcg 840

Qy 841 GGCGCCCTGTGAACCTGATGGGAACCTCTCTGTGACACCCCTCCGTGTTCTTGCCTGCCCA 900
 |||

Db 841 ggcgccctgtgaacctgatgggaacctctctgtgacaccctccgtgttcttgctgcccc 900

Qy 901 TCTTCTCCGCTTTTGGGATGAAGATGATAGCCAGGGCTGTTGTTTGGGGCCCTTCAAGG 960
 |||

Db 901 tcttctccgcttttgggatgaagatgatagccagggtgtgttttggggcccttcaagg 960

Qy 961 CAAAAGACCAGGCTGACTGGAAGATGGAAAGCCACAGGAAGGAAGCGGCACCTGATGGTG 1020
 |||

Db 961 caaaagaccagctgactggaagatggaaagccacaggaaggaagcggcacctgatggtg 1020

Qy 1021 ATCTTGGCACTCTCCATGTTCTCTACAAGAAGCTGTGGTGATTGGCCCTGTGGTCTATCA 1080
 |||

Db 1021 atcttggcactctccatgttctctacaagaagctgtggtgattggccctgtggtctatca 1080

Qy 1081 GGCGAAAACCACAGATTCTCCTTAGTTAGTATAGCGCAAAAAGCTTCTCGAGAGTACT 1140
 |||

Db 1081 ggcgaaaaccacagattctccttctagttagtatagcgcaaaaagcttctcgagagtact 1140

Qy 1141 TCTAGAGCGGCCGCGGCCCATCGATTTCACCCGGGTGGGGTACC 1187
 |||

Db 1141 tctagagcgccgcgggcccatcgattttccaccgggtgggggtacc 1187

RESULT 4

AAX10455/c

ID AAX10455 standard; DNA; 127 BP.

XX

AC AAX10455;

XX

DT 30-MAR-1999 (first entry)

XX

DE Human biallelic polymorphic DNA fragment WI-11758.

XX

KW Polymorphism; biallelic; human; forensic; paternity testing; disease;
 KW detection; phenotypic typing; characteristic; infection; hereditary;
 KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
 KW treatment; marker; ss.

XX

OS Homo sapiens.

XX

PN WO9820165-A2.

XX

PD 14-MAY-1998.

XX

PF 05-NOV-1997; 97WO-US20313.

XX

PR 06-NOV-1996; 96US-0030455.

XX

PA (WHED) WHITEHEAD INST BIOMEDICAL RES.

XX

PI Hudson T, Lander ES, Wang D;

XX

DR WPI; 1998-286974/25.

XX

PT New isolated nucleic acid segments from the human genome - used for
 PT determining polymorphic forms for use in e.g. forensics, paternity
 PT testing or phenotypic typing for disease

XX

PS Claim 1; Page 52; 310pp; English.

XX

CC AAX10269-X12937 are human DNA fragments which contain biallelic
 CC polymorphic markers which have been isolated using the primers
 CC represented in AAX09121-X10268. The base occupying the polymorphic site
 CC is indicated by the appropriate IUPAC-IUB ambiguity code. These fragments
 CC can be used in methods for determining polymorphic forms in an individual
 CC for use in e.g. forensics, paternity testing or for phenotypic typing for
 CC diseases such as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan

CC syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease,
CC familial hypercholesterolemia, polycystic kidney disease, hereditary
CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC autoimmune diseases, inflammation, cancer, diseases of the nervous
CC system, infection by pathogenic microorganisms, and characteristics such
CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC endurance, fertility, and susceptibility or receptivity to particular
CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC segments can also be used to produce medicaments for the treatment or
CC prophylaxis of such diseases.

SQ Sequence 127 BP; 35 A; 30 C; 25 G; 36 T; 1 other;

Query Match 8.9%; Score 106; DB 19; Length 127;
Best Local Similarity 98.1%; Pred. No. 5.9e-17;
Matches 106; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Yy 1013 TGATGGTGATCTTGGCACTCTCCATGTTCTCTACAAGAAGCTGTGGTGATTGGCCCTGTG 1072
 |||
 Db 127 TGATGGTGATCTTGGCACTCTCCATGTTCTCTACAAGAAGCTGTGGTGATTGGCCCTGTG 68

QY 1073 GTCTATCAGGCGAAAACCACAGATTCTCCTTCTAGTTAGTATAGCGCA 1120
 . ||||:|||||||||||||||||||||||||||||||